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SUMMARY 
Human plasma k a l l i k r e i n (HuPK) was detected i n normal non-
a c t i v a t e d and d i l u t i o n - a c t i v a t e d plasma by immunoblotting, using 
p o l y c l o n a l antibodies. In non-activated plasma, the predominatly 
detected p r o t e i n corresponds to p r o k a l l i k r e i n (Mr 80,000-
90,000). A c t i v a t e d plasma, besides k a l l i k r e i n , contains l a r g e r 
proteins (Mr > 130,000) that p o s s i b l y represent complexes 
between k a l l i k r e i n and proteinase i n h i b i t o r s . Plasma a l s o 
contains species (Mr 43,000) which corresponds to k a l l i k r e i n 
heavy chain. In a c t i v a t e d plasma, monoclonal antibodies against 
k a l l i k r e i n heavy chain detected, besides these same bands 
described above, two a d d i t i o n a l bands (Mr 30,000 and 20,000) 
pos s i b l y correspondent to fragments of k a l l i k r e i n heavy chain. 
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INTRODUCTION 
Human plasma k a l l i k r e i n i s a serine proteinase present i n 
plasma as p r o k a l l i k r e i n , a glycoprotein zymogen synthesized by 
l i v e r as a s i n g l e polypeptide chain with 619 aminoacid residues. 
The a c t i v a t i o n of p r o k a l l i k r e i n to k a l l i k r e i n requires the 
cleavage of the peptide bond A r g 3 7 1 - I l e 3 T 2 i n the s i n g l e chain, 
forming a molecule with a heavy chain (371 residues) and a l i g h t 
chain (248 residues) held together by d i s s u l f i d e bridges (1). 
P r o k a l l i k r e i n c i r c u l a t e s i n plasma complexed with high 
molecular weight kininogen as a bimolecular complex 1:1 (2), 
being the heavy chain of p r o k a l l i k r e i n bound to the l i g h t - c h a i n 
of high molecular weight kininogen (3). 
P r o k a l l i k r e i n i s activa t e d i n blood by a c t i v a t e d f a c t o r 
XII (4). K a l l i k r e i n i t s e l f a ctivates f a c t o r XII at the e a r l y 
phase of i n t r i n s i c blood coagulation (5), and hydrolyzee high 
molecular weight kininogen l i b e r a t i n g the hypotensive peptide 
bradykinin (6). Plasma k a l l i k r e i n also p a r t i c i p a t e s i n some 
reactions of f i b r i n o l y s i s (7) and complement systems* (8), and 
promotes the aggregation of p l a t e l e t s (9) and leucocytes (10). 
Plasma k a l l i k r e i n can be found i n two d i f f e r e n t molecular 
weight species (Mr 88,000 and 85,000) (11). The NH2-terminal 
heavy chain (43,000) i s important f o r the s p e c i f i c a c t i v i t y of 
k a l l i k r e i n and i s s i m i l a r to the heavy chain of f a c t o r XI (12); 
the COOH-terminal l i g h t chain (Mr 36,000-33,000) lodges the 
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c a t a l y t i c s i t e of k a l l i k r e i n , and i s s i m i l a r to t r y p s i n (1). 
K a l l i k r e i n i s i n a o t i v a t e d e i t h e r by plasma i n h i b i t o r s 
such as C l - i n h i b i t o r , alpha 2-macroglobulin, antithrombin I I I 
(13) and p r o t e i n C i n h i b i t o r (14), or by the l i v e r , where i t i s 
recognized by i t s alpha-galactose residues (15). 
In t h i s report, we studied the p r o t e o l y s i s of human 
plasma k a l l i k r e i n i n a c t i v a t e d human plasma, as an a l t e r n a t i v e 
c o n t r o l of plasma k a l l i k r e i n metabolization. 
MATERIAL AND METHODS 
Human plasma k a l l i k r e i n (HuPK) was i s o l a t e d from Cohn's 
f r a c t i o n IV (16) or f r e s h plasma (17). The materials were 
submitted to SBTI-Sepharose chromatography (0.02 M t r i s - H C l , 
0.3 M NaCl, pH 8.0 buffer) and the adsorbed k a l l i k r e i n was 
eluted by benzamidine 1.0 M. The pr o t e i n concentration was 
ca l c u l a t e d according to the mesurement of the e x t i n c t i o n 
c o e f f i c i e n t ( E 2 S 0 , 1 X = 1 0 . 6 ) , determined by Nagase and B a r r e t t 
(18). The heavy and l i g h t chains of plasma k a l l i k r e i n were 
i s o l a t e d by reduction w i t h d i t h i o t h r e i t o l , a l k y l a t i o n w i t h 
iodoacetamide (19) and separated on SBTI-Sepharose. 
P o l y c l o n a l antibodies against HuPK were r a i s e d i n 
ra b b i t s . The antiserum was p u r i f i e d on HuPK-Sepharose (0.05 M 
t r i s - H C l , 0.15 M NaCl, pH 8.0 b u f f e r ) , and the bound a n t i b o d i e s 
were eluted with 0.2 M glycine-HCl, pH 2.0 bu f f e r , and the pH of 
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the c o l l e c t e d samples was kept at 8.0 by a d d i t i o n of 1.0 M t r i s . 
Antibody against r a b b i t IgG (second antibody) was r a i s e d i n 
goats, and anti-serum was p u r i f i e d on anti-HuPK-Sepharose, by 
the same procedure. 
Monoclonal antibodies (PR 9) against heavy chain of HuPK, 
k i n d l y provided by Prof. Dr. Werner M u l l e r - K s t e r l ( U n i v e r s i t y of 
Mainz-Qermany), were p r e c i p i t a t e d from a s c i t i c f l u i d s with 
saturated ammonium s u l f a t e s o l u t i o n , pH 7.0 (11:9, v/v). The 
s o l u t i o n was kept at 4°C during 60 minutes and centrifuged at 
3,500 X g at 4°C f o r 30 minutes. The p e l l e t was ressuspended i n 
50% ammonium s u l f a t e s o l u t i o n and recentrifuged, under the same 
conditions. This p e l l e t was ressuspended i n 0.01 M t r i s - H C l , 
pH 7.5 buffer and d i a l y z e d against the same b u f f e r , overnight at 
room temperature. The antibodies were cromatographed on a column 
(100 ml) of DHAE-Sepharose CL 6B (0.01 M t r i s - H C l , pH 7.5 
b u f f e r ) , and eluted w i t h a sodium c h l o r i d e gradient from 0 to 
0.25 M. The PK9 antibodies were eluted w i t h 0.14 M sodium 
c h l o r i d e . 
Antibodies were l a b e l l e d with iodine-125 using as oxidant 
reagents e i t h e r Iodo-beads (Pierce) or Chloramine T (20). The 
s p e c i f i c a c t i v i t y of the p o l y c l o n a l or monoclonal antibodies was 
10-20 uCi/ug, and i n each experiment 2 x 10° cpm (100 rig of 
protein) were used. 
Human normal blood was c o l l e c t e d d i r e c t e l y into p l a s t i c 
tubes mixed with sodium c i t r a t e s o l u t i o n 3.8%, 9:1 (v/v). The 
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sample was centrifugea at 1,500 x g, during 15 minutes at 4°C, 
and the separated plasma was aliquoted and kept frozen at -20°C. 
For a c t i v a t i o n , plasma samples (2 u l ) were thawed, 
d i l u t e d i n water i n a f i n a l volume of 200 u l , and incubated at 
37°C during 15 minutes. The a c t i v a t i o n r e a c t i o n was stopped by 
f r e e z i n g , and the samples were submitted to electrophoresis. 
Control samples of non activated plasma (2 u l ) were thawed and 
d i l u t e d d i r e c t l y i n electrophoresis b u f f e r . 
Sodium dodecyl s u l f a t e Polyacrylamide g e l electrophoresis 
(SDS-PAGE) was performed i n slab gels from 5% to 15%, according 
to the method of Laemmli (21), with 3% stacking gels. Apparent 
molecular weights were determined by running standard proteins 
of known molecular weights (range 14,000 to 200,000) on the g e l . 
Immunoblotting was performed according to the 
modification described by Burnette et a l . (22) or according to 
Kyhse-Andersen (23). The immunodetection of the antigen was 
achieved by a double antibody r e a c t i o n : the n i t r o c e l l u l o s e 
membranes were incubated with anti-HuPK antibody (20 ug/ml) and 
the complexes were developed with 1 2 ö I - s e c o n d antibody (2 x 10 s 
cpm per assay). A l t e r n a t i v e l y , the immunodetection of the 
antigens was achieved by reaction with the monoclonal antibody 
against heavy chain 1 2 Ö I - P K 9 (2 x 10° cpm per assay). 
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RESULTS 
Human plasma k a l l i k r e i n was p u r i f i e d by a described 
procedure (16, 17) and the two known forms, alpha and beta, 
were prepared; both préparâtion8 resulted i n s i n g l e bands on 
non reduced gel elec t r o p h o r e s i s (Figure l a ) . 
a b 
1 2 3 4 5 6 
K a l l i k r e i n 
Heavy chain 
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Fragments 
of heavy 
chain 
FIGURE 1: SDS-polyacrylamide electrophoresis of k a l l i k r e i n 
(HuPK) forms. 
a. Non reduced g e l 
1. alpha-HuPK (15 ug) 
2. alpha-HuPK and beta-HuPK (20 ug) 
3. beta-HuPK (10 ug) 
b. Reduced gel 
4. alpha-HuPK (15 ug) 
5. alpha-HuPK and beta-HuPK (20 ug) 
6. beta-HuPK (10 ug) 
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A f t e r reduction with DTT, alpha-HuPK presente a heavy 
chain (Mr 45,000) and a l i g h t chain (Mr 36,000 and 33,000); 
beta-HuPK has i t s heavy chain hydrolyzed i n t o two bands (Mr 
30,000 and 20,000), and a l i g h t chain (Mr 36,000 and 33,000). 
On an immunoblotting using anti-HuPK and 12°I-eecond 
antibodies, i n non-activated plasma ( f i g u r e 2a) p r o k a l l i k r e i n 
gives a strong band (Mr 80,000) and a l s o weak (Mr > 150,000) 
bands. The 100-fold d i l u t e d plasma ( f i g u r e 2b) presents the same 
p r o k a l l i k r e i n - k a l l i k r e i n band (Mr 80,000), and the high 
molecular bands (Mr > 130,000), that represent k a l l i k r e i n -
i n h i b i t o r complexes. The activa t e d plasma also e x h i b i t s a band 
(Mr 43,000) that corresponds to the p u r i f i e d heavy-chain of the 
enzyme used as marker i n the experiment ( f i g u r e 2d); t h i s band 
does not coincide with IgG fragments which may contaminate 
k a l l k r e i n preparations ( f i g u r e 2c). 
The same experiment indicated i n f i g u r e 2 was performed 
with a monoclonal antibody against heavy chain (PK9). D i l u t e d 
human plasma (1:100) was incubated with p u r i f i e d HuPK or i t s 
i s o l a t e d heavy chain and the antigens were immunoprecipitated 
with 12ÖI-PK9 (fi g u r e 3). 
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P r o k a l l i k r e i n 
or k a l l i k r e i n 
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FIGURE 2: A c t i v a t i o n of human normal plasma by d i l u t i o n (1:100). 
a. human plasma (2 u l ) 
b. human plasma (2 u l ) d i l u t e d 1:100 
c. human IgG (6.5 ug) 
d. i s o l a t e d heavy chain of HuPK (1.0 ug) 
Immunoprecipitation: anti-HuPK 
Development: 12°I-second antibodies 
In a c t i v a t e d plasma the monoclonal antibodies (PK9) 
i d e n t i f i e d k a l l i k r e i n (Mr 80,000) and l a r g e r proteins (Mr > 
130,000); i n t h i s case, the higher molecular weight complexes 
correspond to k a l l i k r e i n - i n h i b i t o r e complexes, and not to 
eventual complexes between free l i g h t chain of HuPK and 
i n h i b i t o r s , because the monoclonal PK9 used to develop the 
b l o t t i n g does not react with l i g h t chain (24). 
The a d d i t i o n of i s o l a t e d k a l l i k r e i n heavy chain to 
act i v a t e d plasma causes a strong enhancement of the weak pr o t e i n 
band (Mr 43,000), showing that the band corresponds to heavy 
chain. 
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FIGURE 3: D i l u t e d human plasma (1:100) incubated with p u r i f i e d 
k a l l i k r e i n and k a l l i k r e i n heavy chain. 
1. human normal plasma (2 u l ) 
2. human normal plasma (2 u l ) and HuPK (0.5 ug) 
3. human normal plasma (2 u l ) and i s o l a t e d heavy chain (0.3 ug) 
4. HuPK (0.5 ug) 
5. i s o l a t e d heavy chain (0.3 ug) 
Development: "°I-PK9 
Plasma (2 u l ) was d i l u t e d (1:100) and incubated with 
increasing q u a n t i t i e s of p u r i f i e d HuPK, and the antigens were 
immunoprecipitated with 12°I-PK9 (f i g u r e 4). The increasing 
q u a n t i t i e s of p u r i f i e d k a l l i k r e i n added to activated plasma 
causes a strong enhancement of the k a l l i k r e i n - i n h i b i t o r s 
complexes bands (Mr > 130,000), as w e l l as the heavy chain band 
(Mr 43,000), and also the appearance of smaller proteins bands 
(Mr 30,000 and 20,000). These r e s u l t s are the f i r s t i n d i c a t i o n 
of the hyd r o l y s i s of k a l l i k r e i n heavy chain, i n plasma. 
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FIGURE 4: Diluted human plasma (1:100) incubated with d i f f e r e n t 
q u a n t i t i e s of HuPK. 
1. human plasma (2 u l ) 
2. human plasma (2 u l ) and HuPK (0.5 ug) 
3. human plasma (2 u l ) and HuPK (1.0 ug) 
4. human plasma (2 u l ) and HuPK (2.5 ug) 
5. HuPK (2.5 ug) 
6. HC (0.2 ug) 
Development: 1 2 Ö I - P K 9 
DISCUSSION 
Beta-HuPK derives from a clevage i n the heavy chain of 
the alpha-HuPK, and one p o s s i b i l i t y f o r t h i s m o d i f i c a t i o n i s to 
occur to keep pure k a l l i k r e i n s o l u t i o n s at room temperature. The 
beta form has the same a c t i v i t y on synthetic substrates, but 
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a l p h a - k a l l i k r e i n cleaves high molecular weight kininogen 
(HMWKgn) r e l e a s i n g b r a y k i n i n , f a s t e r than the beta form (25). 
Contact of plasma with negatively charged surfaces, such 
as glass or k a o l i n , causes ths a c t i v a t i o n of the i n t r i n s i c 
pathway of blood c l o t t i n g , by bringing together k a l l i k r e i n , 
kininogen and faotor XII on the surface. However, d i l u t i o n 
induces a c t i v a t i o n by decreasing the i n h i b i t o r concentration i n 
plasma and thus promoting a c t i v a t i o n of the key c l o t t i n g 
enzymes. In our experiments the a c t i v a t i o n was confirmed by the 
formation of complexes, equivalent to those formed by incubation 
of k a l l i k r e i n and p u r i f i e d i n h i b i t o r s (13). 
Only i n the activa t e d plasma the protein band 
corresponding to the heavy chain (Mr 43,000) was detected by 
both p o l y c l o n a l and monoclonal antibodies (26). The addition of 
large q u a n t i t i e s of a c t i v e k a l l i k r e i n i n a c t i v a t e d plasma brings 
evidences that the transformation of alpha to b e t a - k a l l i k r e i n 
proceeds i n the plasma, as i t was observed f o r p u r i f i e d samples 
of k a l l i k r e i n . The l a r g e r protein bands (Mr > 130,000) probably 
correspond to complexes of k a l l i k r e i n and plasma proteinase 
i n h i b i t o r s . The polypeptide chains with Mr < 43,000 may i n d i c a t e 
that k a l l i k r e i n or i t s heavy chain i s being processed i n 
act i v a t e d plasma, r e s u l t i n g i n shorter fragments. 
No corresponding free l i g h t chain i s found i n ac t i v a t e d 
plasma containing f r e e heavy chain. One possible explanation f o r 
t h i s f i n d i n g i s an extensive hydrolysis of the l i g h t chain, and 
no immunnodetectable fragments would be a v a i l a b l e f o r re a c t i o n 
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w i t h p o l y c l o n a l antibodies. Or, a l t e r n a t i v e l y , the formation of 
l i g h t c h a i n - i n h i b i t o r s complexes might occur but d i f f i c u l t to 
resolve from the HuPK-inibitor complexes. 
Thus, the c o n t r o l of k a l l i k r e i n a c t i v i t y , e s p e c i a l l y i n 
the blood c l o t t i n g cascade, might also be exerted by a 
p r o t e o l y t i c degradation of i t s molecule. The r e s u l t i n g free 
heavy chain might a l t e r the surface binding a b i l i t y of high 
molecular weight kininogen, and the whole a c t i v i t y of the 
contact phase would be lowered. P r o t e o l y s i s of the heavy chain 
i t s e l f might also be taken as part of t h i s c o n t r o l mechanism, 
that would not depend on i n h i b i t i o n and l i v e r clearance alone. 
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